Method and compositions for ordering restriction fragments

ABSTRACT

The invention provides a method for constructing a high resolution physical map of a polynucleotide. In accordance with the invention, nucleotide sequences are determined at the ends of restriction fragments produced by a plurality of digestions with a plurality of combinations of restriction endonucleases so that a pair of nucleotide sequences is obtained for each restriction fragment. A physical map of the polynucleotide is constructed by ordering the pairs of sequences by matching the identical sequences among the pairs.

This is a divisional application of U.S. patent application Ser. No.09/028,128 filed Feb. 23, 1998, now U.S. Pat. No. 6,054,276 which isincorporated herein by reference.

FIELD OF THE INVENTION

The invention relates generally to methods for construction of physicalmaps of DNA, especially genomic DNA, and more particularly, to a methodof providing high resolution physical maps by sequence analysis ofconcatenations of segments of restriction fragment ends.

BACKGROUND

Physical maps of one or more large pieces of DNA, such as a genome orchromosome, consist of an ordered collection of molecular landmarks thatmay be used to position, or map, a smaller fragment, such as clonecontaining a gene of interest, within the larger structure, e.g. U.S.Department of Energy, “Primer on Molecular Genetics,” from Human Genome1991-92 Program Report; and Los Alamos Science, 20: 112-122 (1992). Animportant goal of the Human Genome Project has been to provide a seriesof genetic and physical maps of the human genome with increasingresolution, i.e. with reduced distances in basepairs between molecularlandmarks, e.g. Murray et al, Science, 265: 2049-2054 (1994); Hudson etal, Science, 270: 1945-1954 (1995); Schuler et al, Science, 274: 540-546(1996); and so on. Such maps have great value not only in furthering ourunderstanding of genome organization, but also as tools for helping tofill contig gaps in large-scale sequencing projects and as tools forhelping to isolate disease-related genes in positional cloning projects,e.g. Rowen et al, pages 167-174, in Adams et al, editors, Automated DNASequencing and Analysis (Academic Press, New York, 1994); Collins,Nature Genetics, 9: 347-350 (1995); Rossiter and Caskey, Annals ofSurgical Oncology, 2: 14-25 (1995); and Schuler et al (cited above). Inboth cases, the ability to rapidly construct high-resolution physicalmaps of large pieces of genornic DNA is highly desirable.

Two important approaches to genomic mapping include the identificationand use of sequence tagged sites (STS's), e.g. Olson et al, Science,245: 1434-1435 (1989); and Green et al, PCR Methods and Applications, 1:77-90 (1991), and the construction and use of jumping and linkinglibraries, e.g. Collins et al, Proc. Natl. Acad. Sci., 81: 6812-6816(1984); and Poustka and Lehrach, Trends in Genetics, 2: 174-179 (1986).The former approach makes maps highly portable and convenient, as mapsconsist of ordered collections of nucleotide sequences that allowapplication without having to acquire scarce or specialized reagents andlibraries. The latter approach provides a systematic means foridentifying molecular landmarks spanming large genetic distances and forordering such landmarks via hybridization assays with members of alinking library.

Unfortunately, these approaches to mapping genomic DNA are difficult andlaborious to implement. It would be highly desirable if there was anapproach for constructing physical maps that combined the systematicquality of the jumping and linking libraries with the convenience andportability of the STS approach.

SUMMARY OF THE INVENTION

Accordingly, an object of my invention is to provide methods andmaterials for constructing high resolution physical maps of genomic DNA.

Another object of my invention is to provide a method of orderingrestriction fragments from multiple enzyme digests by aligning matchingsequences of their ends.

Still another object of my invention is to provide a high resolutionphysical map of a target polynucleotide that permits directed sequencingof the target polynucleotide with the sequences of the map.

Another object of my invention is to provide vectors for excising endsof restriction fragments for concatenation and sequencing.

Still another object of my invent is to provide a method monitoring theexpression of genes.

A further object of my invention is to provide physical maps of genomicDNA that consist of an ordered collection of nucleotide sequences spacedat an average distance of a few hundred to a few thousand bases.

My invention achieves these and other objects by providing methods andmaterials for determining the nucleotide sequences of both ends ofrestriction fragments obtained from multiple enzymatic digests of atarget polynucleotide, such as a fragment of a genome, or chromosome, oran insert of a cosmid, BAC, YAC, or the like. In accordance with theinvention, a polynucleotide is separately digested with differentcombinations of restriction endonucleases and the ends of therestriction fragments are sequenced so that pairs of sequences from eachfragment are produced. A physical map of the polynucleotide isconstructed by ordering the pairs of sequences by matching the identicalsequences among such pairs resulting from all of the digestions.

In the preferred embodiment, a polynuclcotide is mapped by the followingsteps: (a) providing a plurality of populations of restrictionfragments, the restriction fragments of each population having endsdefined by digesting the polynucleotide with a plurality of combinationsof restriction endonucleases; (b) determining the nucleotide sequence ofa portion of each end of each restriction fragment of each population sothat a pair of nucleotide sequences is obtained for each restrictionfragment of each population; and (c) ordering the pairs of nucleotidesequences by matching the nucleotide sequences between pairs to form amap of the polynucleotide.

Another aspect of the invention is the monitoring gene expression byproviding pairs of segments excised from cDNAs. In this embodiment,segments from each end of each cDNA of a population of cDNAs are ligatedtogether to form pairs, which serve to identify their associated cDNAs.Concatenations of such pairs are sequenced by conventional techniques toprovide information on the relative frequencies of expression in thepopulation.

The invention provides a means for generating a high density physicalmap of target polynucleotides based on the positions of the restrictionsites of predetermined restriction endonucleases. Such physical mapsprovide many advantages, including a more efficient means for directedsequencing of large DNA fragments, the positioning of expressionsequence tags and cDNA sequences on large genomic fragments, such as BAClibrary inserts, thereby making positional candidate mapping easier; andthe like.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 graphically illustrates the concept of a preferred embodiment ofthe invention.

FIG. 2 provides a diagram of a vector for forming pairs of nucleotidesequences in accordance with a preferred embodiment of the invention.

FIG. 3 illustrates a scheme for carrying out the steps of a preferredembodiment of the invention.

FIG. 4 illustrates locations on yeast chromosome 1 where sequenceinformation is provided in a physical map based on digestions with HindIII, Eco RI, and Xba I in accordance with the invention.

DEFINITIONS

As used herein, the process of “mapping” a polynucleotide meansproviding a ordering, or series, of sequenced segments of thepolynucleotide that correspond to the actual ordering of the segments inthe polynucleotide. For example, the following set of five-basesequences is a map of the polynucleotide below (SEQ ID NO: 1), which hasthe ordered set of sequences making up the map underlined:

(gggtc, ttatt, aacct, catta, ccgga)

GTTGGGTCAACAAATTACCTTATTGTAACCTTCGCATTAGCCGGAGCCT

The term “oligonucleotide” as used herein includes linear oligomers ofnatural or modified monomers or linkages, includingdeoxyribonucleosides, ribonucleosides, and the like, capable ofspecifically binding to a target polynucleotide by way of a regularpattern of monomer-to-monomer interactions, such as Watson-Crick type ofbase pairing, base stacking, Hoogsteen or reverse Hoogsteen types ofbase pairing, or the like. Usually monomers are linked by phosphodiesterbonds or analogs thereof to form oligonucleotides ranging in size from afew monomeric units, e.g. 3-4, to several tens of monomeric units, e.g.40-60. Whenever an oligonucleotide is represented by a sequence ofletters, such as “ATGCCTG,” it will be understood that the nucleotidesare in 5′→3′ order from left to right and that “A” denotesdeoxyadenosine, “C” denotes deoxycytidine, “G” denotes deoxyguanosine,and “T” denotes thymnidine, unless otherwise noted. Usuallyoligonucleotides comprise the four natural nucleotides; however, theymay also comprise non-natural nucleotide analogs. It is clear to thoseskilled in the art when oligonucleotides having natural or non-naturalnucleotides may be employed, e.g. where processing by enzymes is calledfor, usually oligonucleotides consisting of natural nucleotides arerequired.

“Perfectly matched” in reference to a duplex means that the poly- orotigonucleotide strands making up the duplex form a double strandedstructure with one other such that every nucleotide in each strandundergoes Watson-Crick basepairing with a nucleotide in the otherstrand. The term also comprehends the pairing of nucleoside analogs,such as deoxyinosine, nucleosides with 2-aminopurine bases, and thelike, that may be employed. In reference to a triplex, the term meansthat the triplex consists of a perfectly matched duplex and a thirdstrand in which every nucleotide undergoes Hoogsteen or reverseHoogsteen association with a basepair of the perfectly matched duplex.

As used herein, “nucleoside” includes the natural nucleosides, including2′-deoxy and 2′-hydroxyl forms, e.g. as described in Kornberg and Baker,DNA Replication, 2nd Ed. (Freeman, San Francisco, 1992). “Analogs” inreference to nucleosides includes synthetic nucleosides having modifiedbase moieties and/or modified sugar moieties, e.g. described by Scheit,Nucleotide Analogs (John Wiley, New York, 1980); Uhlman and Peyman,Chemical Reviews, 90: 543-584 (1990), or the like, with the only provisothat they are capable of specific hybridization. Such analogs includesynthetic nucleosides designed to enhance binding properties, reducecomplexity, increase specificity, and the like.

As used herein, the term “complexity” in reference to a population ofpolynucleotides means the number of different species of polynucleotidepresent in the population.

DETAILED DESCRIPTION OF THE INVENTION

In accordance with the present invention, segments of nucleotides ateach end of restriction fragments produced from multiple digestions of apolynucleotide are sequenced and used to arrange the fragments into aphysical map. Such a physical map consists of an ordered collection ofthe nucleotide sequences of the segments immediately adjacent to thecleavage sites of the endonucleases used in the digestions. Preferably,after each digestion, segments are removed from the ends of eachrestriction fragment by cleavage with a type uIs restrictionendonuclease. Excised segments from the same fragment are ligatedtogether to form a pair of segments. Preferably, collections of suchpairs are concatenated by ligation, cloned, and sequenced usingconventional techniques.

The concept of the invention is illustrated in FIG. 1 for an embodimentwhich employs three restriction endonucleases: r, q, and s.Polynucleotide (50) has recognition sites (r₁, r₂, r₃, and r₄) forrestriction endonucleases r, recognition sites (q₁ through q₄) forrestriction endonuclease q, and recognition sites (s₁ through s₅) forrestriction endonuclease s. In accordance with the preferred embodiment,polynucleotide (50) is separately digested with r and s, q and s, and rand q to produce three populations of restriction fragments (58), (60),and (62), respectively. Segments adjacent to the ends of eachrestriction fragment are sequenced to form sets of pairs (52), (54), and(56) of nucleotide sequences, which for sake of illustration are showndirectly beneath their corresponding restriction fragments in thecorrect order. Pairs of sequences from all three sets are ordered bymatching sequences between pairs as shown (70). A nucleotide sequence(72) from a first pair is matched with a sequence (74) of a second pairwhose other sequence (76), In turn, is matched with a sequence (78) of athird pair. The matching continues, as (80) is matched with (82), (84)with (86), (88) with (90), and so on, until the maximum number of pairsare included. It is noted that some pairs (92) do not contribute to themap. These correspond to fragments having the same restriction site atboth ends. In other word, they correspond to situations where there aretwo (or more) consecutive restriction sites of the same type withoutother sites in between, e.g. s₃ and s₄ in this example. Preferably,algorithms used for assembling a physical map from the pairs ofsequences can eliminate pairs having identical sequences.

Generally, a plurality of enzymes is employed in each digestion.Preferably, at least three distinct recognition sites are used. This canbe accomplished by using three or more restriction endonucleases, suchas Hind III, Eco RI, and Xba I, which recognize different nucleotidesequences, or by using restriction endonucleases recognizing the samenucleotide sequence, but which have different methylation sensitivities.That is, it is understood that a different “recognition site” may bedifferent solely by virtue of a different methylation state. Preferably,a set of at least three recognition endonucleases is employed in themethod of the invention. From this set a plurality of combinations ofrestriction endonucleases is formed for separate digestion of a targetpolynucleoitde. Preferably, the combinations are “n−1” combinations ofthe set. In other words, for a set of n restriction endonucleases, thepreferred combinations are all the combinations of n−1 restrictionendonucleases. For example, as illustrated in FIG. 1 where a set ofthree restriction endonucleases (r, q, and s) are employed, the n−1combinations are (r, q), (r, s), and (q, s). Likewise, if fourrestriction endonucleases (r, q, s, and w) are employed, the n−1combinations are (r, q, s), (r, q, w), (r, s, w), and (q, s, w). It isreadily seen that where a set of n restriction endonucleases areemployed the plurality of n−1 combinations is n.

Preferably, the method of the invention is carried out using a vector,such as that illustrated in FIG. 2. The vector is readily constructedfrom commercially available materials using conventional recombinant DNAtechniques, e.g. as disclosed in Sambrook et al, Molecular Cloning,Second Edition (Cold Spring Harbor Laboratory, New York, 1989).Preferably, pUC-based plasmids, such as pUC19, or λ-based phages, suchas λZAP Express (Stratagene Cloning Systems, La Jolla, Calif.), or likevectors are employed. Important features of the vector are recognitionsites (204) and (212) for two type IIs restriction endonucleases thatflank restriction fragment (208). For convenience, the two type IIsrestriction enzymes are referred to herein as “IIs₁” and “IIs₂”,respectively. IIs₁ and IIs₂ may be the same or different. Recognitionsites (204) and (212) are oriented so that the cleavage sites of IIs₁and IIs₂ are located in the interior of restriction fragment (208). Inother words, taking the 5′ direction as “upstream” and the 3′ directionas “downstream,” the cleavage site of IIs₁ is downstream of itsrecognition site and the cleavage site of IIs₂ is upstream of itsrecognition site. Thus, when the vector is cleaved with IIs₁ and IIs₂two segments (218) and (220) of restriction fragment (208) remainattached to the vector. The vector is then re-circularized by ligatingthe two ends together, thereby forming a pair of segments, If suchcleavage results in one or more single stranded overhangs, i.e. one ormore non-blunt ends, then the ends are preferably rendered blunt priorto re-circularization, for example, by digesting the protruding strandwith a nuclease such as Mung bean nuclease, or by extending a 3′recessed strand, if one is produced in the digestion. The ligationreaction for re-circularization is carried out under conditions thatfavor the formation of covalent circles rather than concatemers of thevector. Preferably, the vector concentration for the ligation is betweenabout 0.4 and about 4.0 μg/ml of vector DNA, e.g. as disclosed inCollins et al, Proc. Natl. Acad. Sci., 81: 6812-6812 (1984), for λ-basedvectors. For vectors of different molecular weight, the concentrationrange is adjusted appropriately.

In the preferred embodiments, the number of nucleotides identifieddepends on the “reach” of the type IIs restriction endonucleasesemployed. “Reach” is the amount of separation between a recognition siteof a type IIs restriction endonuclease and its cleavage site, e.g.Brenner, U.S. Pat. No. 5,559,675. The conventional measure of reach isgiven as a ratio of integers, such as “(16/14)”, where the numerator isthe number of nucleotides from the recognition site in the 5′→3′direction that cleavage of one strand occurs and the denominator is thenumber of nucleotides from the recognition site in the 3′→5′ directionthat cleavage of the other strand occurs. Preferred type IIs restrictionendonucleases for use as IIs₁ and IIs₂ in the preferred embodimentinclude the following: Bbv I, Bce 83 I, Bcef I, Bpm I, Bsg I, BspLU 11III, Bst 71 I, Eco 57 I, Fok I, Gsu I, Hga I, Mme I, and the like. Inthe preferred embodiment, a vector is selected which does not contain arecognition site, other than (204) and (212), for the type IIs enzyme(s)used to generate pairs of segments; otherwise, re-circularization cannotbe carried out.

Preferably, a type IIs restriction endonuclease for generating pairs ofsegments has as great a reach as possible to maximize the probabilitythat the nucleotide sequences of the segments are unique. This in turnmaximizes the probability that a unique physical map can be assembled.If the target polynucleotide is a bacterial genome of 1 megabase, for arestriction endonuclease with a six basepair recognition site, about 250fragments are generated (or about 500 ends) and the number ofnucleotides determined could be as low as five or six, and still have asignificant probability that each end sequence would be unique.Preferably, for polynucleotides less than or equal to 10 megabases, atleast 8 nucleotides are determined in the regions adjacent torestriction sites, when a restriction endonuclease having a six basepairrecognition site is employed. Generally for polynucleotides less than orequal to 10 megabases, 9-12 nucleotides are preferably determined toensure that the end sequences are unique. In the preferred embodiment,type IIs enzymes having a (16/14) reach effectively provide 9 bases ofunique sequence (since blunting reduces the number of bases to 14 and 5bases are part of the recognition sites (206) or (210)). In apolynucleotide having a random sequence of nucleotides, a 9-mer appearson average about once every 262,000 bases. Thus, 9-mer sequences arequite suitable for uniquely labeling restriction fragments of a targetpolynucleotide corresponding to a typical yeast artificial chromosome(YACs) insert, i.e. 100-1000 kilobases, bacterial artificial chromosome(BAC) insert, i.e. 50-250 kilobases, and the like.

Immediately adjacent to IIs sites (204) and (212) are restriction sites(206) and (210), respectively that permit restriction fragment (208) tobe inserted into the vector. That is, restriction site (206) isimmediately downstream of (204) and (210) is immediately upstream of(212). Preferably, sites (204) and (206) are as close together aspossible, even overlapping, provided type IIs site (206) is notdestroyed upon cleavage with the enzymes for inserting restrictionfragment (208). This is desirable because the recognition site of therestriction endonuclease used for generating the fragments occursbetween the recognition site and cleavage site of type IIs enzyme usedto remove a segment for sequencing, i.e. it occurs within the “reach” ofthe type IIs enzyme. Thus, the closer the recognition sites, the largerthe piece of unique sequence can be removed from the fragment. The sameof course holds for restriction sites (210) and (212). Preferably,whenever the vector employed is based on a pUC plasmid, restrictionsites (206) and (210) are selected from either the restriction sites ofpolylinker region of the pUC plasmid or from the set of sites which donot appeal in the pUC. Such sites include Eco RI, Apo I, Ban II, Sac I,Kpn I, Acc65 I, Ava I, Xma I, Sma I, Bam HI, Xba I, Sal I, Hinc II, AccI, BspMI, Pst I, Sse8387 I, Sph I, Hind III, Afl II, Age I, Bsp120 I,Asc I, Bbs I, Bcl I, Bgl II, Blp I, BsaA I, Bsa BI, Bse RI, Bsm I, ClaI, Bsp EI, BssH II, Bst BI, BstXI, Dra III, Eag I, Eco RV, Fse I, Hpa I,Mfe I, Nae I, Nco I, Nhe I, Not I, Nru I, Pac I, Xho I, Pme I, Sac II,Spe I, Stu I, and the like. Preferably, six-nucleotide recognition sites(i.e. “6-cutters”) are used, and more preferably, 6-cutters leavingfour-nucleotide protruding strands are used.

Preferably, the vectors contain primer binding sites (200) and (216) forprimers p₁ and p₂, respectively, which may be used to amplify the pairof segments by PCR after re-circularization. Recognition sites (202) and(214) are for restriction endonucleases w₁ and w₂, which are used tocleave the pair of segments from the vector after amplification.Preferably, w₁ and w₂, which may be the same or different, are type IIsrestriction endonucleases whose cleavage sites correspond to those of(206) and (210), thereby removing surplus, or non-informative, sequence(such as the recognition sites (204) and (212)) and generatingprotruding ends that permit concatenation of the pairs of segments.

FIG. 3 illustrates steps in a preferred method using vectors of FIG. 2.Genornic or other DNA (400) is obtained using conventional techniques,e.g. Herrmann and Frischauf, Methods in Enzymology, 152: 180-183 (1987);Frischauf, Methods in Enzymology, 152: 183-199 (1987), or the like,after which it is divided (302) into aliquots that are separatelydigested (310) with combinations restriction endonucleases, as shown inFIG. 3 for the n−1 combinations of the set of enzymes r, s, and q.Preferably, the resulting fragments are treated with a phosphatase toprevent ligation of the genornic fragments with one another before orduring insertion into a vector. Restriction fragments are inserted (312)into vectors designed with cloning sites to specifically accept thefragments. That is, fragments digested with r and s are inserted into avector that accepts r-s fragments. Fragments having the same ends, e.g.r-r and s-s, are not cloned since information derived from them does notcontribute to the map. r-s fragments are of course inserted into thevector in both orientations. Thus, for a set of three restrictionendonucleases, only three vectors are required, e.g. one each foraccepting r-s, r-q, and s-q fragments. Likewise, for a set of fourrestriction endonucleases, e.g. r, s, q, and t, only six vectors arerequired, one each for accepting r-s, r-q, r-t, s-q, s-t, and q-tfragments.

After insertion, a suitable host is transformed with the vectors andcultured, i.e. expanded (314), using conventional techniques.Transformed host cells are then selected, e.g. by plating and pickingcolonies using a standard marker, e.g. β-glactosidase/X-gal. A largeenough sample of transformed host cells is taken to ensure that everyrestriction fragment is present for analysis with a reasonably largeprobability. This is similar to the problem of ensuring representationof a clone of a rare mRNA in a cDNA library, as discussed in Sambrook etal, Molecular Cloning, Second Edition (Cold Spring Harbor Laboratory,New York, 1989), and like references. Briefly, the number of fragments,N, that must be in a sample to achieve a given probability, P, ofincluding a given fragment is the following: N=1n(1−P)/In(1−f), where fis the frequency of the fragment in the population. Thus, for apopulation of 500 restriction fragments, a sample containing 3454vectors will include at least one copy of each fragment (i.e. a completeset) with a probability of 99.9%; and a sample containing 2300 vectorswill include at least one copy of each fragment with a probability of99%. The table below provides the results of similar calculations fortarget polynucleotides of different sizes:

TABLE I Average fragment size Average fragment size after cleavage withafter cleavage with 2 six-cutters 3 six-cutters (No. of fragments) (No.of fragments) Size of Target [Sample size for [Sample size forPolynucleotide complete set with 99% complete set with 99% (basepairs)probability] probability] 2.5 × 10⁵   2048 (124) [576]  1365 (250)[1050] 5 × 10⁵ 2048 (250) [1050] 1365 (500) [2300] 1 × 10⁶ 2048 (500)[2300] 1365 (1000) [4605]

After selection, the vector-containing hosts are combined and expandedin cultured. The vectors are then isolated, e.g. by a conventionalmini-prep, or the like, and cleaved with IIs₁ and IIs₂ (316). Thefragments comprising the vector and ends (i.e. segments) of therestriction fragment insert are isolated, e.g. by gel electrophoresis,blunted (316), and re-circularized (320). resulting pairs of segments inthe re-circularized vectors are then amplified (322), e.g. by polymerasechain reaction (PCR), after which the amplified pairs are cleaved with w(324) to free the pairs of segments, which are isolated (326), e.g. bygel electrophoresis. The isolated pairs are concatenated (328) in aconventional ligation reaction to produce concatemers of various sizes,which are separated, e.g. by gel electrophoresis. Concatemers greaterthan about 200-300 basepairs are isolated and cloned (330) into astandard sequencing vector, such as M13. The sequences of the clonedconcatenated pairs are analyzed on a conventional DNA sequencer, such asa model 377 DNA sequencer from Perkin-Elmer Applied Biosystems Division(Foster City, Calif.).

In the above embodiment, the sequences of the pairs of segments arereadily identified between sequences for the recognition site of theenzymes used in the digestions. For example, when pairs are concatenatedfrom fragments of the r and s digestion after cleavage with a type IIsrestriction endonuclease of reach (16/14), the following pattern isobserved (SEQ ID NO: 1):

. . . NNNNrrrrrrNNNNNNNNNNNNNNNNNNqqqqqqNNNNNN . . .

where “r” and “q” represent the nucleotides of the recognition sites ofrestriction endonuclease r and q, respectively, and where the N's arethe nucleotides of the pairs of segments. Thus, the pairs are recognizedby their length and their spacing between known recognition sites.

Pairs of segments are ordered by matching the sequences of segmentsbetween pairs. That is, a candidate map is built by selecting pairs thathave one identical and one different sequence. The identical sequencesare matched to form a candidate map, or ordering, as illustrated belowfor pairs (s₁, s₂), (s₃, s₂), (s₃, s₄), (s₅, s₄), and (s_(5,) s₆), whererepresent the nucleotide sequences of the segments:

Sequence matching and candidate map construction is readily carried outby computer algorithms, such as the Fortran code provided in Appendix A.Preferably, a map construction algorithm initially sorts the pairs toremove identical pairs prior to map construction. That is, preferablyonly one pair of each kind is used in the reconstruction. If for twopairs, (s_(i), s_(j)) and (s_(m), s_(n)), s_(i)=s_(m) and s_(j)=s_(n),then one of the two can be eliminated prior to map construction. Aspointed out above, such additional pairs either correspond torestriction fragments such as (92) of FIG. 1 (no sites of a second orthird restriction endonuclease in its interior) or they are additionalcopies of pairs (because of sampling) that can be used in the analysis.Preferably, an algorithm selects the largest candidate map as asolution, i.e. the candidate map that uses the maximal number of pairs.

The vector of FIG. 2 can also be used for determining the frequency ofexpression of particular cDNAs in a cDNA library. Preferably, cDNAswhose frequencies are to be determined are cloned into a vector by wayof flanking restriction sites that correspond to those of (206) and(210). Thus, cDNAs may be cleaved from the library vectors anddirectionally inserted into the vector of FIG. 2. After insertion,analysis is carried out as described for the mapping embodiment, exceptthat a larger number of concatemers are sequenced in order to obtain alarge enough sample of cDNAs for reliable data on frequencies.

EXAMPLE 1 Constructing a Physical Map of Yeast Chromosome 1 with HindIII, Eco RI, and Xba I

In this example, a physical map of the 230 kilobase yeast chromosome 1is constructed using pUC19 plasmids modified in accordance with FIG. 2.The chromosome is separately digested to completion with the followingcombinations of enzymes: Hind III and Eco RI, Hind III and Xba I, andEco RI and Xba I to generate three populations of restriction fragments.Fragments from each population are inserted into separate pUC19plasmids, one for each restriction fragment having different ends. Thatis, restriction fragments from the Hind III-Eco RI digestion are presentin three types, ones with a Hind III-digested end and an Eco RI-digestedend (“H-E” fragments), one with only Hind III-digested ends (“H-H”fragments), and ones with only Eco RI-digested fragments (“E-E”fragments). Likewise, restriction fragments from the Hind III-Xba Idigestion are present in three types, ones with a Hind III-digested endand an Xba I-digested end (“H-X” fragments), one with only HindIII-digested ends (“H-H” fragments), and ones with only Xba I-digestedfragments (“X-X” fragments). Finally, restriction fragments from the XbaI-Eco RI digestion are present in three types, ones with a XbaI-digested end and an Eco RI-digested end (“X-E” fragments), one withonly Xba I-digested ends (“X-X” fragments), and ones with only EcoRI-digested fragments (“E-E”0 fragments). Thus, the plasmid for the HindRI-Eco RI digestion accepts H-E fragments; the plasmid for the HindIII-Xba I digestion accepts H-X fragments; and the plasmid for the XbaI-Eco RI digestion accepts X-E fragments. The construction of theplasmid for accepting H-E fragments is described below. The otherplasmids are construction in a similar manner. Syntheticoligonucleotides (i) through (iv) are combined with a Eco I- and HindIII-digested pUC19 in a ligation reaction so that they assemble into thedouble stranded insert of Formula I.

Note that the insert has compatible ends to the Eco RI-Hind III-digestedplasmid, but that the original Eco RI and Hind III sites are destroyedupon ligation. The horizontal arrows above and below the Bsg I and Bbv Isites indicate the direction of the cleavage site relative to therecognition site of the enzymes. After ligation, transformation of asuitable host, and expansion, the modified pUC19 is isolated and theinsert is sequenced to confirm its identity.

Yeast chromosome 1 DNA is separated into three aliquots of about 5 μgDNA (0.033 pmol) each, which are then separately digested to completionwith Hind III and Eco RI, Hind III and Xba I, and Eco RI and Xba I,respectively. For each of the three populations, the same procedure isfollowed, which is described as follows for the pUC19 designed for H-Efragments.

Since each enzyme recognizes a six basepair recognition sequence, about100-140 fragments are produced for a total of about 3.3 pmol offragments, about fifty percent of which are H-E fragments. 5.26 μg (3pmol) of plasmid DNA is digested with Eco RI and Hind III in Eco RIbuffer as recommended by the manufacturer (New England Biolabs, Beverly,Mass.), purified by phenol extraction and ethanol precipitation, andligated to the H-E fragments of the mixture in a standard ligationreaction. A bacterial host is transformed, e.g. by electroporation, andplated so that hosts containing recombinant plasmids are identified bywhite colonies. The digestion of the yeast chromosome 1 generates about124 fragments of the three types, about fifty percent of which are H-Efragments and about twenty-five percent each are H-H or E-E fragments.About 290 colonies are picked for H-E fragments, and about 145 each arepicked for H-H and E-E fragments. The same procedure is carried out forall the other types of fragments, so that six populations of transformedhosts are obtained, one each for H-E, H-X, X-E, H-H, E-E, and X-Xfragments. Each of the populations is treated separately as follows:About 10 μg of plasmid DNA is digested to completion with Bsg I usingthe manufacturer's protocol (New England Biolabs, Beverly, Mass.) andafter phenol extraction the vector/segment-containing fragment isisolated, e.g. by gel electrophoresis. The ends of the isolated fragmentare then blunted by Mung bean nuclease (using the manufacturer'srecommended protocol, New England Biolabs), after which the bluntedfragments are purified by phenol extraction and ethanol precipitation.The fragments are then resuspended in a ligation buffer at aconcentration of about 0.05 μg/ml in 20 1-ml reaction volumes. Thedilution is designed to promote self-ligation of the fragments,following the protocol of Collins et al, Proc. Natl. Acad. Sci., 81:6812-6816 (1984). After ligation and concentration by ethanolprecipitation, phages from the 20 reactions are combined. The pairs ofsegments carried by the plasmids are then amplified by PCR using primersp₁ and p_(2.) The amplified product is purified by phenol extraction andethanol precipitation, after which it is cleaved with Bbv I using themanufacturer's recommended protocol (New England Biolabs). Afterisolation by polyacrylamide gel electrophoresis, the pairs areconcatenated by carrying out a conventional ligation reaction. Theconcatenated fragments are then separated by polyacrylamide gelelectrophoresis and concatemers greater than about 200 basepairs areisolated and ligated into an equimolar mixture of three Phagescript SKsequencing vectors (Stratagene Cloning Systems, La Jolla, Calif.),separately digested with Hind III, Eco RI, and Hind III and Eco RI,respectively. (Other appropriate mixtures and digestions are employedwhen different combinations of enzymes are used). Preferably, a numberof clones are expanded and sequenced that ensure with a probability ofat least 99% that all of the pairs of the aliquot are sequenced. A“lane” of sequence data (about 600 bases) obtained with conventionalsequencing provides the sequences of about 25 pairs of segments. Thus,after transfection, about 13 individual clones are expanded andsequenced on a commercially available DNA sequencer, e.g. PE AppliedBiosystems model 377, to give the identities of about 325 pairs ofsegments. The other sets of fragments require an additional 26 lanes ofsequencing (13 each for the H-X and X-E fragments).

FIG. 4 illustrates the positions on yeast chromosome 1 of pairs ofsegments ordered in accordance with the algorithm of Appendix A. Therelative spacing of the segments along the chromosome is only providedto show the distribution of sequence information along the chromosome.

EXAMPLE 2 Directed Sequencing of Yeast Chromosome 1 Using RestrictionMap Sequences as Spaced PCR Primers

In this example, the 14-mer segments making up the physical map ofExample 1 are used to separately amplify by PCR fragments thatcollectively cover yeast 1 chromosome. The PCR products are insertedinto standard M13mp19, or like, sequencing vectors and sequenced in boththe forward and reverse directions using conventional protocols. Forfragments greater than about 800 basepairs, the sequence informationobtained in the first round of sequencing is used to synthesized newsets of primers for the next round of sequencing. Such directedsequencing continues until each fragment is completely sequenced. Basedon the map of Example 1, 174 primers are synthesized for 173 PCRs. Thetotal number of sequencing reactions required to cover yeast chromosome1 depends on the distribution of fragment sizes, and particularly, howmany rounds of sequencing are required to cover each fragment; thelarger the fragment, the more rounds of sequencing that are required forfull coverage. Full coverage of a fragment is obtained when inspectionof the sequence information shows that complementary sequences are beingidentified. Below, it is assumed that conventional sequencing willproduce about 400 bases at each end of a fragment in each round.Inspection shows that the distribution of fragment sizes from theExample 1 map of yeast chromosome 1 are shown below together withreaction and primer requirements:

Number of Number of Round of Fragment Number of Seq. or PCR SequencingSequencing size range Fragments Primers Reactions 1 >0 174 174 3482 >800 92 184 184 3 >1600 53 106 106 4 >2400 28 56 56 5 >3200 16 32 326 >4000 7 14 14 7 >4800 5 10 10 8 >5600 1 2 2 Total No. of 578 752Primers: Seq. reactions 39 for map: Total No. of 791 Reactions:

This compares to about 2500-3000 sequencing reactions that are requiredfor full coverage using sequencing.

Appendix A Computer Code for Ordering Pairs into a Physical Map programopsort c c opsort reads ordered pairs from disk files c p1.dat, p2.dat,and p3.dat. and sorts c them into a physical map. c character*1op(1000,2,14),w(14),x(14) character*1 fp(1000,2,14),test(14) c copen(1,file=′p1.dat′,status=′old′)open(5,file=′olist.dat′,status=′replace′) c c nop=0 read(1,100)nop1nop=nop + nop1 do 101 j=1,nop  read(1,102) (w(i),i=1,14),  +   (x(k),k=1,14) do 121 kk=1,14  op(j,1,kk)=w(kk)  op(j,2,kk)=x(kk) 121 continue 101 continue read(1,100)nop2 nop=nop + nop2 do 1011j=nop1+1,nop  read(1,102) (w(i),i=1,14),  +    (x(k),k=1,14) do 1211kk=1,14  op(j,1,kk)=w(kk)  op(j,2,kk)=x(kk) 1211  continue 1011 continueclose(1) c write(5,110)nop1,nop2,nop 110 format(3(2x,i4)) c copen(1,file=′p2.dat′,status=′old′) read(1,100)nop3 nop=nop + nop3 do 104j=nop1+nop2+1,nop  read(1,102) (w(i),i=1,14),  +    (x(k),k=1,14) do 122kk=1,14  op(j,1,kk)=w(kk)  op(j,2,kk)=x(kk) 122  continue 104 continue cread(1,100)nop4 nop=nop + nop4 do 1041 j=nop1+nop2+nop3+1,nop read(1,102) (w(i),i=1,14),  +    (x(k),k=1,14) do 1221 kk=1,14 op(j,1,kk)=w(kk)  op(j,2,kk)=x(kk) 1221  continue 1041 continue cclose(1) write(5,1108)nop1,nop2,nop3,nop4, nop 1108 format(5(2x,i4)) c copen(1,file=′p3.dat′,status=′old′) read(1,100)nop5 nop=nop + nop5 do 105j=nop1+nop2+nop3+nop4+1,nop  read(1,102) (w(i),i=1,14),  +   (x(k),k=1,14) do 123 kk=1,14  op(j,1,kk)=w(kk)  op(j,2,kk)=x(kk) 123 continue 105 continue c read(1,100)nop6 nop=nop + nop6 do 1051j=nop1+nop2+nop3+nop4+nop5+1,nop  read(1,102) (w(i),i=1,14),  +    (x(k),k=1,14) do 1231 kk=1,14  op(j,1,kk)=w(kk)  op(j,2,kk)=x(kk) 1231 continue 1051 continue c close(1)write(5,1109)nop1,nop2,nop3,nop4,nop5,nop6,nop 1109 format(7(2x,i4)) c c100 format(i4) 102 format(2(2X,14a1)) 111 format(/) c c write (5,111) do120 m=1,nop  write(5,102) (op(m,1,i),i=1,14),  +     (op(m,2,k),k=1,14) write(*,102) (op(m,1,i),i=1,14),  +     (op(m,2,k),k=1,14) 120 continue c c write (5,111) do 1100 i=1,14  test(i)=op(1,2,i)   fp(1,1,i)=op(1,1,i)    fp(1,2,i)=op(1,2,i) 1100  continue c nxx=nopns=1 c 1000 continue ne=0 do 2000 ix=2,nxx  nt=0  do 2100 jx=1,14 if(test(jx).ne.op(ix,1,jx)) then   nt=nt+1   endif 2100 continue if(nt.eq.0) then   ns=ns+1 c   ne=ne+1   if(ne.gt.1) then   write(*,1003) 1003 format(1x,′ne is gt 1′)   endif c   do 2200kx=1,14    fp(ns,1,kx)=op(ix,1,kx)    fp(ns,2,kx)=op(ix,2,kx)   test(kx)=op(ix,2,kx) 2200    continue     mm=0 do 2300 mx=1,nxx    if(mx.eq.ix) then      goto 2300     else      mm=mm+1      do 2400ma=1,14      op(mm,1,ma)=op(mx,1,ma)      op(mm,2,ma)=op(mx,2,ma) 2400     continue     endif 2300     continue   endif 2000   continue  nxx=nxx−1   if(ne.ne.0) then    goto 1000    endif c c do 1220 m=1,ns write(5,102) (fp(m,1,i),i=1,14),  +      (fp(m,2,k),k=1,14) write(*,102) (fp(m,1,i),i=1,14),  +      (fp(m,2,k),k=1,14) 1220 continue write(*,100)ns c close(5) c end

6 40 nucleotides nucleic acid double linear 1 NNNNNNNNNN NNNNNNNNNNNNNNNNNNNN NNNNNNNNNN 40 36 nucleotides nucleic acid single linear 2AATTAGCCGT ACCTGCAGCA GTGCAGAAGC TTGCGT 36 36 nucleotides nucleic acidsingle linear 3 AAACCTCAGA ATTCCTGCAC AGCTGCGAAT CATTCG 36 36nucleotides nucleic acid single linear 4 AGCTCGAATG ATTCGCAGCTGTGCAGGAAT TCTGAG 36 36 nucleotides nucleic acid single linear 5GTTTACGCAA GCTTCTGCAC TGCTGCAGGT ACGGCT 36 72 nucleotides nucleic aciddouble linear 6 AATTAGCCGT ACCTGCAGCA GTGCAGAAGC TTGCGTAAAC CTCAGAATTC50 CTGCACAGCT GCGAATCATT CG 72

I claim:
 1. A vector containing a restriction fragment of DNA, thevector having a top strand and a bottom strand, and comprising, insequence: a first type IIs recognition site oriented in the 5′ to 3′direction of said top strand, said restriction fragment, and a secondtype IIs recognition site oriented in the 5′ to 3′ direction of saidbottom strand, such that a first type IIs restriction endonucleaserecognizing the first type IIs recognition site has a cleavage sitewhich is 3′ of the first recognition site in the top strand 5′ to 3′direction, and is within the restriction fragment, and a second type IIsrestriction endonuclease recognizing the second type IIs recognitionsite has a cleavage site which is 3′ of the second recognition site inthe bottom strand 5′ to 3′ direction, and is within the restrictionfragment.
 2. The vector of claim 1, further including a thirdrestriction site and a fourth restriction site, for accepting saidfragment of DNA, the third restriction site being between said firsttype IIs recognition site and said cleavage site of said first type IIsrecognition site, and the fourth restriction site being between saidsecond type IIs recognition site and said cleavage site of said secondtype IIs recognition site.
 3. The vector of claim 2, further including athird type IIs recognition site, a third type IIs cleavage site, afourth type IIs recognition site and a fourth type IIs cleavage site,wherein the third type IIs cleavage site is identical to that of thethird restriction site of claim 2, and the fourth type IIs cleavage siteis identical to that of the fourth restriction site of claim
 2. 4. Thevector of claim 1, wherein said first type IIs restriction endonucleaseand second type IIs restriction endonuclease are the same.
 5. The vectorof claim 3, wherein said first and second type IIs recognition sites areBsgI sites, said third and fourth restriction sites are HindIII andEcoRI sites, respectively, and said third and fourth type IIsrecognition sites are BbvI sites, as shown in the following sequence(SEQ ID NO: 6):                 BbvI  BsgI  HindIII           EcoRI  BsgI   BbvI5′-AATTAGCCGTACCTGCAGCAGTGCAGAAGCTTGCGTAAACCTCAGAATTCCTGCACAGCTGCGAATCATTCG-3′    3′-TCGGCATGGACGTCGTCACGTCTTCGAACGCATTTGGAGTCTTAAGGACGTGTCGACGCTTAGTAAGCTCGA-5′                 BbvI  BsgI  HindIII           EcoRI  BsgI   BbvI.